Literature DB >> 26233698

Office-Based Opioid Treatment with Buprenorphine (OBOT-B): Statewide Implementation of the Massachusetts Collaborative Care Model in Community Health Centers.

Colleen T LaBelle1, Steve Choongheon Han2, Alexis Bergeron3, Jeffrey H Samet4.   

Abstract

We describe a Massachusetts Bureau of Substance Abuse Services' (BSAS) initiative to disseminate the office-based opioid treatment with buprenorphine (OBOT-B) Massachusetts Model from its development at Boston Medical Center (BMC) to its implementation at fourteen community health centers (CHCs) beginning in 2007. The Massachusetts Collaborative Care Model for the delivery of opioid agonist therapy with buprenorphine, in which nurses working with physicians play a central role in the evaluation and monitoring of patients, holds promise for the effective expansion of treatment for opioid use disorders. The training of and technical assistance for the OBOT nurses as well as a limited program assessment are described. Data spanning 6years (2007-2013) report patient demographics, prior treatment for opioid use disorders, history of overdose, housing, and employment. The expansion of OBOT to the fourteen CHCs increased the number of physicians who were "waivered" (i.e., enabling their prescribing of buprenorphine) by 375%, from 24 to 114, within 3years. During this period the annual admissions of OBOT patients to CHCs markedly increased. Dissemination of the Massachusetts Model of the Office-Based Opioid Treatment with Buprenorphine employing a collaborative care model with a central role for nursing enabled implementation of effective treatment for patients with an opioid use disorder at community health centers throughout Massachusetts while effectively engaging primary care physicians in this endeavor.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Access to treatment; Buprenorphine; Nurse care manager; Opioid agonist therapy; Opioid use disorder; Waivered physicians

Mesh:

Substances:

Year:  2015        PMID: 26233698      PMCID: PMC4682362          DOI: 10.1016/j.jsat.2015.06.010

Source DB:  PubMed          Journal:  J Subst Abuse Treat        ISSN: 0740-5472


  11 in total

1.  Improving chronic illness care: translating evidence into action.

Authors:  E H Wagner; B T Austin; C Davis; M Hindmarsh; J Schaefer; A Bonomi
Journal:  Health Aff (Millwood)       Date:  2001 Nov-Dec       Impact factor: 6.301

Review 2.  Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation.

Authors:  A T McLellan; D C Lewis; C P O'Brien; H D Kleber
Journal:  JAMA       Date:  2000-10-04       Impact factor: 56.272

3.  Implementation science in the real world: a streamlined model.

Authors:  Herschel Knapp; Henry D Anaya
Journal:  J Healthc Qual       Date:  2012 Nov-Dec       Impact factor: 1.095

4.  Barriers and facilitators to primary care or human immunodeficiency virus clinics providing methadone or buprenorphine for the management of opioid dependence.

Authors:  Barbara J Turner; Christine Laine; Yi-Ting Lin; Kevin Lynch
Journal:  Arch Intern Med       Date:  2005 Aug 8-22

5.  Collaborative care of opioid-addicted patients in primary care using buprenorphine: five-year experience.

Authors:  Daniel P Alford; Colleen T LaBelle; Natalie Kretsch; Alexis Bergeron; Michael Winter; Michael Botticelli; Jeffrey H Samet
Journal:  Arch Intern Med       Date:  2011-03-14

6.  Experiences of a national sample of qualified addiction specialists who have and have not prescribed buprenorphine for opioid dependence.

Authors:  Wendy Kissin; Caroline McLeod; Joseph Sonnefeld; Arlene Stanton
Journal:  J Addict Dis       Date:  2006

7.  Integrating buprenorphine maintenance therapy into federally qualified health centers: real-world substance abuse treatment outcomes.

Authors:  Marwan S Haddad; Alexei Zelenev; Frederick L Altice
Journal:  Drug Alcohol Depend       Date:  2013-01-17       Impact factor: 4.492

8.  Integrating buprenorphine treatment into office-based practice: a qualitative study.

Authors:  Declan T Barry; Kevin S Irwin; Emlyn S Jones; William C Becker; Jeanette M Tetrault; Lynn E Sullivan; Helena Hansen; Patrick G O'Connor; Richard S Schottenfeld; David A Fiellin
Journal:  J Gen Intern Med       Date:  2008-12-17       Impact factor: 5.128

Review 9.  The Clinical Opiate Withdrawal Scale (COWS).

Authors:  Donald R Wesson; Walter Ling
Journal:  J Psychoactive Drugs       Date:  2003 Apr-Jun

10.  Treating homeless opioid dependent patients with buprenorphine in an office-based setting.

Authors:  Daniel P Alford; Colleen T LaBelle; Jessica M Richardson; James J O'Connell; Carole A Hohl; Debbie M Cheng; Jeffrey H Samet
Journal:  J Gen Intern Med       Date:  2007-02       Impact factor: 5.128

View more
  74 in total

1.  Buprenorphine Initiation and Linkage to Outpatient Buprenorphine do not Reduce Frequency of Injection Opiate Use Following Hospitalization.

Authors:  Phoebe A Cushman; Jane M Liebschutz; Bradley J Anderson; Merredith R Moreau; Michael D Stein
Journal:  J Subst Abuse Treat       Date:  2016-06-11

2.  From policy to practice: Pilot program increases access to medication for opioid use disorder in rural Colorado.

Authors:  Tanya R Sorrell; Mary Weber; Andrea Alvarez; Nancy Beste; Ursula Hollins; Claudia R Amura; Paul F Cook
Journal:  J Subst Abuse Treat       Date:  2020-05-07

3.  Management of Opioid Misuse and Opioid Use Disorders Among Youth.

Authors:  Camille A Robinson; J Deanna Wilson
Journal:  Pediatrics       Date:  2020-05       Impact factor: 7.124

4.  Improving Adherence to Long-term Opioid Therapy Guidelines to Reduce Opioid Misuse in Primary Care: A Cluster-Randomized Clinical Trial.

Authors:  Jane M Liebschutz; Ziming Xuan; Christopher W Shanahan; Marc LaRochelle; Julia Keosaian; Donna Beers; George Guara; Kristen O'Connor; Daniel P Alford; Victoria Parker; Roger D Weiss; Jeffrey H Samet; Julie Crosson; Phoebe A Cushman; Karen E Lasser
Journal:  JAMA Intern Med       Date:  2017-09-01       Impact factor: 21.873

5.  Patient Barriers and Facilitators to Medications for Opioid Use Disorder in Primary Care.

Authors:  Babak Tofighi; Arthur Robin Williams; Chemi Chemi; Selena Suhail-Sindhu; Vicky Dickson; Joshua D Lee
Journal:  Subst Use Misuse       Date:  2019-08-20       Impact factor: 2.164

6.  Tapering off and returning to buprenorphine maintenance in a primary care Office Based Addiction Treatment (OBAT) program.

Authors:  Zoe M Weinstein; Gabriela Gryczynski; Debbie M Cheng; Emily Quinn; David Hui; Hyunjoong W Kim; Colleen Labelle; Jeffrey H Samet
Journal:  Drug Alcohol Depend       Date:  2018-06-19       Impact factor: 4.492

7.  Effects of Global Payment and Accountable Care on Medication Treatment for Alcohol and Opioid Use Disorders.

Authors:  Julie M Donohue; Colleen L Barry; Elizabeth A Stuart; Shelly F Greenfield; Zirui Song; Michael E Chernew; Haiden A Huskamp
Journal:  J Addict Med       Date:  2018 Jan/Feb       Impact factor: 3.702

8.  A pilot study of mindful body awareness training as an adjunct to office-based medication treatment of opioid use disorder.

Authors:  Cynthia J Price; Joseph O Merrill; Rachelle L McCarty; Kenneth C Pike; Judith I Tsui
Journal:  J Subst Abuse Treat       Date:  2019-05-23

9.  The Washington State Hub and Spoke Model to increase access to medication treatment for opioid use disorders.

Authors:  Sharon Reif; Mary F Brolin; Maureen T Stewart; Thomas J Fuchs; Elizabeth Speaker; Shayna B Mazel
Journal:  J Subst Abuse Treat       Date:  2019-07-19

10.  A comparison of buprenorphine and psychosocial treatment outcomes in psychosocial and medical settings.

Authors:  Ned J Presnall; D A Patterson Silver Wolf; Derek S Brown; Sara Beeler-Stinn; Richard A Grucza
Journal:  J Subst Abuse Treat       Date:  2019-06-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.